XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
$ in Thousands
 3 Months Ended
Mar. 31, 2022
USD ($)
AstraZeneca Agreements [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 $ (171,516)
Additions (15,945)
Recognized as Revenue 16,223
Balance at March 31, 2022 (171,238)
Product Revenue, Net [Member] | Direct Sales [Member] | Contract Liabilities [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (3,176)
Additions (407)
Deduction 835
Currency Translation and Other (11)
Balance at March 31, 2022 (2,759)
Drug Product Revenue [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (39,036)
Additions (51,386)
Reclassified to Accrued Liability 60,834
Balance at March 31, 2022 (29,588)
Drug Product Revenue [Member] | AstraZeneca Agreements [Member] | U.S. [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (11,171)
Reclassified to Accrued Liability 11,171
Drug Product Revenue [Member] | Astellas Agreement [Member] | Japan [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (1,974)
Additions (2,226)
Reclassified to Accrued Liability 4,200
Drug Product Revenue [Member] | Astellas Agreement [Member] | Europe [Member]  
Contract with Customer Liability [Line Items]  
Balance at December 31, 2021 (25,891)
Additions (49,160)
Reclassified to Accrued Liability 45,463
Balance at March 31, 2022 $ (29,588)